more_reports

The Latest Regenerative Medicine Articles from Streetwise Reports

One Co. With Cell Holding Device Stands Out in T1D Space

Research Report
  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.
Tags: Medical DevicesRegenerative Medicine

Cell Pouch Co. Peer Aborts Program Using Like Device

Research Report
  ()
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report.
Tags: Medical DevicesRegenerative Medicine

Regenerative Medicine Firm OK'd To Advance Trial in T1D

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication.
Tags: Medical DevicesRegenerative Medicine

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative

  ()
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced."
Tags: Regenerative MedicineBiotechnology / Pharmaceuticals

Two Firms Aim To Create Functional Cure for Type 1 Diabetes

  ()
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs.
Tags: Medical DevicesRegenerative Medicine

New Blood Cancer Treatment Shows Continued Response

Research Report
  ()
The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report.
Tags: Regenerative Medicine

Regenerative Med Co. Granted Second Tissue License

Research Report
  ()
With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report.
Tags: Regenerative Medicine

Showing Results: 1 to 7 of 7